ATE61731T1 - Wirksubstanzen enthaltende hydrogelvorrichtungen, worin das konzentrationsprofil der wirksubstanz einen sigmoidalen konzentrationsgradienten zur konstanten freisetzung besitzt, deren herstellung und verwendung. - Google Patents

Wirksubstanzen enthaltende hydrogelvorrichtungen, worin das konzentrationsprofil der wirksubstanz einen sigmoidalen konzentrationsgradienten zur konstanten freisetzung besitzt, deren herstellung und verwendung.

Info

Publication number
ATE61731T1
ATE61731T1 AT85810213T AT85810213T ATE61731T1 AT E61731 T1 ATE61731 T1 AT E61731T1 AT 85810213 T AT85810213 T AT 85810213T AT 85810213 T AT85810213 T AT 85810213T AT E61731 T1 ATE61731 T1 AT E61731T1
Authority
AT
Austria
Prior art keywords
active agent
manufacture
devices containing
constant release
sigmoidal
Prior art date
Application number
AT85810213T
Other languages
German (de)
English (en)
Inventor
Ping I Dr Lee
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Application granted granted Critical
Publication of ATE61731T1 publication Critical patent/ATE61731T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Colloid Chemistry (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
AT85810213T 1984-05-10 1985-05-07 Wirksubstanzen enthaltende hydrogelvorrichtungen, worin das konzentrationsprofil der wirksubstanz einen sigmoidalen konzentrationsgradienten zur konstanten freisetzung besitzt, deren herstellung und verwendung. ATE61731T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/608,756 US4624848A (en) 1984-05-10 1984-05-10 Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
EP85810213A EP0164311B1 (en) 1984-05-10 1985-05-07 Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use

Publications (1)

Publication Number Publication Date
ATE61731T1 true ATE61731T1 (de) 1991-04-15

Family

ID=24437841

Family Applications (1)

Application Number Title Priority Date Filing Date
AT85810213T ATE61731T1 (de) 1984-05-10 1985-05-07 Wirksubstanzen enthaltende hydrogelvorrichtungen, worin das konzentrationsprofil der wirksubstanz einen sigmoidalen konzentrationsgradienten zur konstanten freisetzung besitzt, deren herstellung und verwendung.

Country Status (16)

Country Link
US (1) US4624848A (enEXAMPLES)
EP (1) EP0164311B1 (enEXAMPLES)
JP (1) JPS619A (enEXAMPLES)
AT (1) ATE61731T1 (enEXAMPLES)
AU (1) AU583507B2 (enEXAMPLES)
CA (1) CA1246447A (enEXAMPLES)
DE (1) DE3582193D1 (enEXAMPLES)
DK (1) DK205185A (enEXAMPLES)
ES (1) ES542948A0 (enEXAMPLES)
FI (1) FI851801A7 (enEXAMPLES)
GR (1) GR851114B (enEXAMPLES)
IL (1) IL75129A (enEXAMPLES)
NZ (1) NZ212030A (enEXAMPLES)
PH (1) PH24100A (enEXAMPLES)
PT (1) PT80416B (enEXAMPLES)
ZA (1) ZA853511B (enEXAMPLES)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749576A (en) * 1984-05-10 1988-06-07 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
JPS61218517A (ja) * 1985-03-25 1986-09-29 Bio Materiaru Yunibaasu:Kk 経皮吸収製剤
FR2585246A1 (fr) * 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
US4794002A (en) * 1985-11-01 1988-12-27 Monsanto Company Modified polymeric surfaces and process for preparing same
JPH0643851B2 (ja) * 1986-03-13 1994-06-08 大同メタル工業株式会社 軸受ユニット
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4780236A (en) * 1986-06-20 1988-10-25 Kiwi Brands, Inc. Lavoratory cleansing block containing polyethylene gycol disteatrate, guar gum and sodium chloride
US4743248A (en) * 1986-08-11 1988-05-10 Alza Corporation Dosage form for delivering acid sensitive beneficial agent
GB8620845D0 (en) * 1986-08-28 1986-10-08 Reckitt & Colmann Prod Ltd Treatment of textile surfaces
US5219575A (en) * 1987-06-26 1993-06-15 Duphar International Research B.V. Compositions with controlled zero-order delivery rate and method of preparing these compositions
EP0297650A1 (en) * 1987-06-26 1989-01-04 Duphar International Research B.V Compositions with controlled zero-order delivery rate and method of preparing these compositions
US4910015A (en) * 1987-10-19 1990-03-20 Massachusetts Institute Of Technology Surface-active polysiloxanes and drug releasing materials thereof
GB8801863D0 (en) * 1988-01-28 1988-02-24 Fulmer Yarsley Ltd Pharmaceutical formulations with controlled drug release
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
WO1996024330A1 (en) 1995-02-10 1996-08-15 Medtronic, Inc. Method and device for administering analgesics
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US6039968A (en) * 1997-06-24 2000-03-21 Hoechst Marion Roussel Intravaginal drug delivery device
DE19843904A1 (de) * 1998-09-24 2000-03-30 Basf Ag Feste Dosierungsform mit polymerem Bindemittel
DE19843903A1 (de) * 1998-09-24 2000-03-30 Basf Ag Feste Dosierungsform mit copolymerem Bindemittel
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
US7943162B2 (en) * 1999-10-21 2011-05-17 Alcon, Inc. Drug delivery device
JP4100910B2 (ja) * 1999-12-23 2008-06-11 ファイザー・プロダクツ・インク ヒドロゲル駆動の薬物剤形
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
GB0027357D0 (en) * 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
WO2003009774A2 (en) 2001-07-23 2003-02-06 Alcon, Inc. Ophthalmic drug delivery device
CA2446741C (en) * 2001-07-23 2009-09-29 Alcon, Inc. Ophthalmic drug delivery device
EP1441703B1 (en) * 2001-10-29 2018-01-03 Massachusetts Institute of Technology Zero-order release profile dosage form manufactured by three-dimensional printing
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
GB2401547B (en) 2003-05-08 2005-07-20 Nektar Therapeutics Uk Ltd Particulate materials
GB0310636D0 (en) * 2003-05-08 2003-06-11 Nektar Therapeutics Uk Ltd Particulate materials
KR20060082792A (ko) * 2003-07-10 2006-07-19 알콘, 인코퍼레이티드 안과용 약물 전달 장치
US20060246109A1 (en) * 2005-04-29 2006-11-02 Hossainy Syed F Concentration gradient profiles for control of agent release rates from polymer matrices
CA2623940C (en) * 2005-09-27 2017-01-10 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and methods of use
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
KR20120107533A (ko) 2005-11-28 2012-10-02 마리누스 파마슈티컬스 ｇａｎａｘｏｌｏｎｅ 제형, 이의 제조방법 및 용도
US8246973B2 (en) 2006-06-21 2012-08-21 Advanced Cardiovascular Systems, Inc. Freeze-thaw method for modifying stent coating
CA2657435A1 (en) 2006-07-10 2008-07-03 Medipacs, Inc. Super elastic epoxy hydrogel
EP2056818B1 (en) 2006-08-11 2011-05-25 The Johns Hopkins University Compositions and methods for neuroprotection
EP2201840B1 (en) 2006-09-22 2011-11-02 Pharmacyclics, Inc. Inhibitors of Bruton's Tyrosine Kinase
CA2699157A1 (en) 2007-09-10 2009-03-19 Calcimedica, Inc. Compounds that modulate intracellular calcium
JP2011505520A (ja) 2007-12-03 2011-02-24 メディパックス インコーポレイテッド 流体計量供給装置
EP2321303B1 (en) 2008-08-27 2019-11-27 Calcimedica, Inc. Compounds that modulate intracellular calcium
ES2559029T3 (es) 2009-04-24 2016-02-10 Tissue Tech, Inc. Composiciones que contienen al complejo HC.HA y metodos de uso de las mismas
WO2011032011A1 (en) 2009-09-10 2011-03-17 Medipacs, Inc. Low profile actuator and improved method of caregiver controlled administration of therapeutics
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
US9500186B2 (en) 2010-02-01 2016-11-22 Medipacs, Inc. High surface area polymer actuator with gas mitigating components
EP2558866B1 (en) 2010-04-15 2016-08-17 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
US8754219B2 (en) 2010-04-27 2014-06-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
AU2011248877B9 (en) 2010-04-27 2015-11-05 Calcimedica Inc. Compounds that modulate intracellular calcium
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
AU2011293201B2 (en) 2010-08-27 2015-11-05 Calcimedica Inc. Compounds that modulate intracellular calcium
WO2012061556A1 (en) 2010-11-03 2012-05-10 Flugen, Inc. Wearable drug delivery device having spring drive and sliding actuation mechanism
CA2767773C (en) 2011-02-11 2015-11-24 Grain Processing Corporation Composition comprising a salt and a crystallization interrupter
WO2012149486A1 (en) 2011-04-28 2012-11-01 Tissuetech, Inc. Methods of modulating bone remodeling
ES2822301T3 (es) 2011-06-10 2021-04-30 Tissuetech Inc Métodos de procesamiento de tejidos de soporte fetal
NZ621221A (en) 2011-09-13 2016-07-29 Pharmacyclics Llc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
WO2013103973A1 (en) 2012-01-06 2013-07-11 Abide Therapeutics Carbamate compounds and of making and using same
JP2015510956A (ja) 2012-03-14 2015-04-13 メディパックス インコーポレイテッド 過剰反応性分子を含むスマートポリマー材料
AU2013271918C1 (en) 2012-06-04 2017-02-09 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
CA2878163A1 (en) 2012-07-11 2014-01-16 Tissuetech, Inc. Compositions containing hc-ha/ptx3 complexes and methods of use thereof
WO2014052914A1 (en) 2012-09-28 2014-04-03 University Of Washington Through Its Center For Commercialization Compounds and methods for preventing, treating and/or protecting against sensory hair cell death
WO2014059333A1 (en) 2012-10-12 2014-04-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9611263B2 (en) 2013-10-08 2017-04-04 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP3077388A1 (en) 2013-12-05 2016-10-12 Pharmacyclics, LLC Inhibitors of bruton's tyrosine kinase
EP3134418A4 (en) 2014-04-23 2018-01-03 The Research Foundation for The State University of New York A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
US9775978B2 (en) 2014-07-25 2017-10-03 Warsaw Orthopedic, Inc. Drug delivery device and methods having a retaining member
US10080877B2 (en) 2014-07-25 2018-09-25 Warsaw Orthopedic, Inc. Drug delivery device and methods having a drug cartridge
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
CN107438613B (zh) 2015-02-06 2020-08-25 华盛顿大学 用于预防或治疗感觉毛细胞死亡的化合物和方法
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
US20160243288A1 (en) 2015-02-23 2016-08-25 Tissuetech, Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
CA2977521C (en) 2015-02-27 2024-03-19 Curtana Pharmaceuticals, Inc. 1-(aryl)-3-(heteroaryl) urea compounds and their use as olig2 inhibitors
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
MA41827A (fr) 2015-03-27 2018-01-30 Pharmacyclics Llc Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
MA41828A (fr) 2015-03-27 2018-01-30 Pharmacyclics Llc Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
HK1252658A1 (zh) 2015-05-11 2019-05-31 H. Lundbeck A/S. 治疗炎症或神经性疼痛的方法
CA2984443A1 (en) 2015-05-20 2016-11-24 Tissuetech, Inc. Compositions and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells
US20170209462A1 (en) 2015-08-31 2017-07-27 Pharmacyclics Llc Btk inhibitor combinations for treating multiple myeloma
US10076650B2 (en) 2015-11-23 2018-09-18 Warsaw Orthopedic, Inc. Enhanced stylet for drug depot injector
JP2019505498A (ja) 2015-12-16 2019-02-28 ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ Ｎｋ細胞におけるサイトカイン誘導性ｓｈ２タンパク質の阻害
HK1259434A1 (zh) 2016-01-19 2019-11-29 Janssen Pharmaceutica Nv 包含btk抑制剂的配制品/组合物
DK3405178T3 (da) 2016-01-19 2025-09-22 Janssen Pharmaceutica Nv Formuleringer/sammensætninger, der omfatter en btk-inhibitor
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
WO2017147146A1 (en) 2016-02-23 2017-08-31 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists
AU2017246334C1 (en) 2016-04-04 2022-11-17 Sinopia Biosciences, Inc. Treating extrapyramidal syndrome using Trapidil
WO2017205534A1 (en) 2016-05-25 2017-11-30 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
USD802756S1 (en) 2016-06-23 2017-11-14 Warsaw Orthopedic, Inc. Drug pellet cartridge
WO2018005600A1 (en) * 2016-06-28 2018-01-04 Trustees Of Tufts College Compositions and methods for delivery of active agents
SG11201900405XA (en) 2016-07-18 2019-02-27 Arthrosi Therapeutics Inc Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia
BR112019003973A2 (pt) 2016-08-26 2019-10-08 Curtana Pharmaceuticals Inc inibição de atividade olig2
US10434261B2 (en) 2016-11-08 2019-10-08 Warsaw Orthopedic, Inc. Drug pellet delivery system and method
LT3541807T (lt) 2016-11-16 2021-12-27 H. Lundbeck A/S Magl inhibitoriaus kristalinė forma
MX393241B (es) 2016-11-16 2025-03-24 H Lundbeck As Formulaciones farmaceuticas.
DK3675865T3 (da) 2017-09-01 2025-05-26 Univ Washington Krystallinske former af forbindelser til forebyggelse eller behandling af sensorisk hårcelledød
WO2019169112A1 (en) 2018-02-28 2019-09-06 Curtana Pharmaceuticals, Inc. Inhibition of olig2 activity
US10717712B2 (en) 2018-07-27 2020-07-21 Concentric Analgesics, Inc. Pegylated prodrugs of phenolic TRPV1 agonists
AU2019392750B2 (en) 2018-12-06 2025-07-10 Arthrosi Therapeutics, Inc. Methods for treating or preventing gout or hyperuricemia
BR112021010708A2 (pt) 2018-12-06 2021-08-24 Arthrosi Therapeutics, Inc. Formas cristalinas de um composto para tratar ou prevenir gota ou hiperuricemia
JP7536767B2 (ja) 2018-12-31 2024-08-20 バイオメア フュージョン，インコーポレイテッド メニン－ｍｌｌ相互作用の不可逆的阻害剤
US12377082B2 (en) 2019-03-15 2025-08-05 Unicycive Therapeutics Inc. Nicorandil derivatives
WO2021214550A1 (en) 2020-04-21 2021-10-28 H. Lundbeck A/S Synthesis of a monoacylglycerol lipase inhibitor
EP4149934A4 (en) 2020-05-11 2024-05-15 Cleave Therapeutics, Inc. CRYSTALLINE FORMS AND FORMULATIONS OF A VCP/P97 INHIBITOR
EP4263542A1 (en) 2020-12-16 2023-10-25 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
CA3204457A1 (en) 2021-01-06 2022-07-14 Ben SESSA Mdma in the treatment of alcohol use disorder
EP4337316A1 (en) 2021-05-11 2024-03-20 Awakn Ls Europe Holdings Limited Therapeutic aminoindane compounds and compositions
IL309073A (en) 2021-06-03 2024-02-01 Arcadia Medicine Inc Enantiomeric entactogen compounds and methods of their use.
WO2023018825A1 (en) 2021-08-11 2023-02-16 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
CA3229150A1 (en) 2021-08-20 2023-02-23 Biomea Fusion, Inc. Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cance
IL311051A (en) 2021-08-23 2024-05-01 Alexander Shulgin Res Institute Inc Fluorinated empathogens
US12043605B2 (en) 2021-08-23 2024-07-23 Alexander Shulgin Research Institute, Inc. Deuterated empathogens
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
EP4396162A2 (en) 2021-09-03 2024-07-10 Alexander Shulgin Research Institute, Inc. Asymmetric allyl tryptamines
WO2023039240A1 (en) 2021-09-13 2023-03-16 Biomea Fusion, Inc. IRREVERSIBLE INHIBITORS OF KRas
US20250066386A1 (en) 2021-11-09 2025-02-27 Biomea Fusion, Inc. Inhibitors of kras
MX2024008057A (es) 2021-12-30 2024-08-28 Biomea Fusion Inc Compuestos de pirazina como inhibidores de flt3.
WO2023139163A1 (en) 2022-01-19 2023-07-27 Awakn Ls Europe Holdings Limited 1,3-benzodioxole esters and their therapeutic use
EP4479404A1 (en) 2022-02-16 2024-12-25 Awakn Ls Europe Holdings Limited Bridged ring compounds and their therapeutic use as cns agents
WO2023235618A1 (en) 2022-06-03 2023-12-07 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
CN119836422A (zh) 2022-07-06 2025-04-15 奥比兰制药有限公司 S1p受体调节剂的结晶形式
TW202430528A (zh) 2023-01-18 2024-08-01 美商拜歐米富士恩股份有限公司 Ｎ－［４－［４－（４－嗎啉基）－７ｈ－吡咯並［２，３－ｄ］嘧啶－６－基］苯基］－４－［［３（ｒ）－［（１－氧代－２－丙烯－１－基）氨基］－１－哌啶基］甲基］－２－吡啶甲醯胺的結晶形式作為ｍｅｎｉｎ－ｍｌｌ相互作用的共價抑制劑
US20250002458A1 (en) 2023-05-24 2025-01-02 Unicycive Therapeutics Inc. Salt forms of nicorandil derivative
WO2024249950A1 (en) 2023-06-02 2024-12-05 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
US20250145571A1 (en) 2023-09-26 2025-05-08 Unicycive Therapeutics, Inc. Amino acid prodrugs of nicorandil
WO2025194102A1 (en) 2024-03-15 2025-09-18 Unicycive Therapeutics, Inc. Pyridine modified nicorandil derivatives

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH468192A (de) * 1964-06-19 1969-02-15 Ciba Geigy Verfahren zur Herstellung von Arzneimitteln in Perlenform
ES335314A1 (es) * 1966-01-06 1967-12-01 Ceskoslovenska Akademie Ved Mejoras introducidas en la preparacion de vehiculos insolubles de sustancias al menos parcialmente solubles, biologicamente activas.
US3660071A (en) * 1966-07-26 1972-05-02 Nat Patent Dev Corp Water soluble entrapping of a pesticide
US3660563A (en) * 1966-07-26 1972-05-02 Nat Patent Dev Corp Water soluble entrapping of a drug
US3577512A (en) * 1968-10-11 1971-05-04 Nat Patent Dev Corp Sustained release tablets
US3576760A (en) * 1969-06-13 1971-04-27 Nat Patent Dev Corp Water soluble entrapping
DE2031871C3 (de) * 1970-06-27 1974-06-27 Roehm Gmbh, 6100 Darmstadt Überzugsmasse für Arzneiformen
GB1394990A (en) * 1971-08-12 1975-05-21 Hydrophilics Int Inc Copolymers and compositions containing copolymers
US4056496A (en) * 1972-10-02 1977-11-01 Corneal Sciences, Inc. Hydrogels and articles made therefrom
US4070348A (en) * 1973-07-25 1978-01-24 Rohm Gmbh Water-swellable, bead copolymer
US4007258A (en) * 1973-09-10 1977-02-08 Union Corporation Sustained release pesticidal composition
US4178361A (en) * 1973-09-10 1979-12-11 Union Corporation Sustained release pharmaceutical composition
CH621561A5 (en) * 1974-01-14 1981-02-13 Ceskoslovenska Akademie Ved Process for producing a bromocyan-activated, hydrophilic, polymeric carrier for biologically active compounds in dried form
US3923939A (en) * 1974-06-07 1975-12-02 Alza Corp Process for improving release kinetics of a monolithic drug delivery device
US4177056A (en) * 1974-06-27 1979-12-04 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers used as carriers for medicaments and pesticides
US4248855A (en) * 1976-08-27 1981-02-03 Hydrophilics International, Inc. Pharmaceutical base salts
US4164560A (en) * 1977-01-05 1979-08-14 Folkman Moses J Systems for the controlled release of macromolecules
US4304591A (en) * 1978-01-25 1981-12-08 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers used as carriers for medicaments and pesticides
CA1125698A (en) * 1978-03-09 1982-06-15 Masaru Yoshida Process for preparing a polymer composition
US4267295A (en) * 1979-02-09 1981-05-12 Syntex (U.S.A.) Inc. Polymeric compositions and hydrogels formed therefrom
US4357312A (en) * 1981-07-16 1982-11-02 The Children's Hospital Medical Center Method of making prolonged release body
IL70071A (en) * 1982-11-01 1987-12-31 Merrell Dow Pharma Multilayered sustained release pharmaceutical tablets having non-uniform distribution of active ingredient
US4564364A (en) * 1983-05-26 1986-01-14 Alza Corporation Active agent dispenser
GB8319766D0 (en) * 1983-07-22 1983-08-24 Graham N B Controlled release device

Also Published As

Publication number Publication date
FI851801L (fi) 1985-11-11
EP0164311B1 (en) 1991-03-20
DE3582193D1 (de) 1991-04-25
FI851801A7 (fi) 1985-11-11
IL75129A (en) 1989-08-15
DK205185A (da) 1985-11-11
ES8603273A1 (es) 1986-01-01
NZ212030A (en) 1988-01-08
EP0164311A3 (en) 1987-06-03
PH24100A (en) 1990-03-05
FI851801A0 (fi) 1985-05-08
EP0164311A2 (en) 1985-12-11
IL75129A0 (en) 1985-09-29
US4624848A (en) 1986-11-25
CA1246447A (en) 1988-12-13
GR851114B (enEXAMPLES) 1985-11-25
AU583507B2 (en) 1989-05-04
JPS619A (ja) 1986-01-06
AU4221685A (en) 1985-11-14
ZA853511B (en) 1985-12-24
DK205185D0 (da) 1985-05-09
PT80416A (en) 1985-06-01
PT80416B (en) 1987-04-16
ES542948A0 (es) 1986-01-01

Similar Documents

Publication Publication Date Title
ATE61731T1 (de) Wirksubstanzen enthaltende hydrogelvorrichtungen, worin das konzentrationsprofil der wirksubstanz einen sigmoidalen konzentrationsgradienten zur konstanten freisetzung besitzt, deren herstellung und verwendung.
Lee Kinetics of drug release from hydrogel matrices
DE3581673D1 (de) Abgabevorrichtung zur freisetzung nullter ordnung eines wirkstoffes in eine loesende fluessigkeit, sowie verfahren zu deren herstellung.
ATA326483A (de) Glaskuegelchen mit modifizierter oberflaeche, verfahren zu deren herstellung und verwendung derselben
DE3485618D1 (de) Zusammensetzung zur kontrollierten abgabe eines wirkstoffes und ihre herstellung.
ATE151298T1 (de) Behälter, der mit einer lösung eines aktiven prinzipes imprägnierbar ist, für eine iontophoretische vorrichtung zur transdermalen verabreichung von medikamenten, und verfahren zur herstellung eines solchen behälters
DE3860769D1 (de) Polymer-zusammensetzung, verfahren zu deren herstellung und deren anwendung.
ATE110415T1 (de) Verbessertes verfahren und apparat, um biologische substanzen in lebenden zellen einzuführen.
DE69330640D1 (de) Mikroverkapselung von zellen
DK517782A (da) Fremgangsmaade til udbygning af lipidindholdet af en dyrket nitroorganisme samt carbonfrit kopipapir indeholdende et saaledes udbygget lipid
ATA444779A (de) Transparentes fluessigkeitsverbandmaterial, und verfahren zu seiner herstellung
DE1642821C3 (de) Vorrichtung zum Herstellen eines Objektträgers für elektrophoretisch zu untersuchende Proben, z.B. Blutsera, und Verfahren zum Herstellen eines solchen Objektträgers
Lee et al. Fluoride ion diffusion from a glass–ionomer cement
DE58909724D1 (de) Verwendung einer Vorrichtung mit einem Wirkstoffreservoir für gesteuerte Wirkstoffabgabe
DE3862788D1 (de) Fluessige oxydationsmodifizierte ethylenische statistische copolymere, verfahren zur herstellung und deren verwendung.
Rizzatti-Barbosa et al. Acrylic resin water sorption under different pressure, temperature and time conditions
FR2347674A1 (fr) Dispositif et procede utilisables pour analyser un echantillon en le soumettant a une separation par affinite ou diffusion moleculaire
EP0055299A4 (en) Antibiotic y-16482 alpha and/or antibiotic y16482 beta, process for their preparation, and medicinal composition containing the same.
BR7700252A (pt) Processo e solucao liquida para tratamento de um meio selecionado com um material de tratamento relativamente insoluvel,em particular para tratamento de uma substancia celulosica,com um fungicida
ES2073454T3 (es) Soporte para moleculas biologicamente activas o a su vez biologicamente activo, su procedimiento de preparacion y su aplicacion en biologia.
Mullon et al. A Mathematical Analysis of the U-Shaped Hybrid Artificial Pancreas-A Novel Insulin Release Rate Equation
Bortolami et al. Ultrastructural observations on the tapetum lucidum fibrosum
Pywell et al. Drug release from polymeric, multi-perforated, laminated matrices
IT8948446A0 (it) Dispositivo per la diffusione capillare e orientata del liquido di pastura contenuto nelle esche,nei piombi o negli affondatori per la pesca alla traina
Fabergé Oriented Preparations of Free-Floating Asymmetrical Cells or Cell Constituents by Their Inclusion in Extruded Fibers

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee